To further standardize the management of vaccination units, the Specifications for Vaccination (2023 version) proposes hierarchical management. However, guidelines for establishing, implementing, and evaluating such a framework remain underdeveloped. This paper systematically reviews the current status of hierarchical management in vaccination units, clarifies its feasibility and necessity, and proposes an implementation scheme.

To further standardize the management of vaccination units, the Specifications for Vaccination (2023 version) proposes hierarchical management. However, guidelines for establishing, implementing, and evaluating such a framework remain underdeveloped. This paper systematically reviews the current status of hierarchical management in vaccination units, clarifies its feasibility and necessity, and proposes an implementation scheme.

Objective·To investigate the evolution of sarcoma antigen 1(SAGE1),a member of the cancer-testis antigen(CTA)family,in three representative primate species—Macaca mulatta(Rhesus),Callithrix jacchus(Marmoset),and Microcebus murinus(Mouse Lemur),as well as the conservation of its interaction with INTS3,a subunit of the integrator complex.Methods·The interaction between INTS3 and SAGE1 in these primates and the interaction between INTS3 and human SAGE1 mutants were first validated in HEK293T cells by using co-immunoprecipitation(Co-IP).Truncated proteins were then tagged with His-SUMO and GST,respectively,and expressed in Escherichia coli,followed by a series of purification steps to obtain the target proteins.Surface plasmon resonance(SPR)was used to measure the binding affinity of the target proteins,and size exclusion chromatography with multi-angle light scattering(SEC-MALS)was used to determine the stoichiometry of the complex.Additionally,molecular docking was employed to predict the binding model of the truncated SAGE1 and INTS3.Mutations were performed on human SAGE1 key interface residues to analyze their binding to INTS3 by Co-IP.Results·The interaction between the full-length human-derived INTS3 and the full-length SAGE1 from the three primate species was confirmed by Co-IP.Truncated proteins were purified through multiple steps of tandom chromatography.The dissociation constants of the three pairs of truncated INTS3-SAGE1 were measured via SPR,and the SEC-MALS results demonstrated that the binding ratio of INTS3-SAGE1 was 2∶1.Furthermore,molecular docking predicted a structural model of the truncated INTS3-SAGE1 complex and the binding interface was extensively constituted with hydrophobic contacts assisted by some hydrophilic interactions.The interaction between the mutant SAGE1 and INTS3 full-length protein was significantly weakened.Conclusion·There is a conserved interaction between INTS3 and SAGE1 across Rhesus,Marmoset,and Mouse lemur.

Objective:To establish an index that can reflect the level of healthy aging promotion in a region.Methods:Establish an indicators system using expert consultation and then determine the weight for each indicator using the analytic hierarchy process. Finally, we can get the regional healthy aging promotion index.Results:Regional healthy aging promotion indicator system was established, including five first-level indicators (residence environment, medical service, public health, nurse and care, and supporting system) and 21 second-level indicators. The weight of every level-one indicator ranges from 0.073 to 0.346. Two indicators with the highest weight are residence environment and public health (0.346 and 0.325, respectively), while the indicator with the lowest weight is nurse and care (0.073). The importance of every level-two indicator ranges from 0.011 to 0.162. The consistency ratio of the regional healthy aging promotion index is 0.021, and the consistency test is qualified.Conclusion:Regional healthy aging promotion index established in this study is very scientific, reasonable, and applicable. It can be used to evaluate the region's situation or level of healthy aging promotion.

Objective:To explore the clinical significance of anti-Crohn′s disease antibody binding polypeptide (anti-CABP) in the diagnosis of inflammatory bowel disease (IBD) .Methods:Clinical data of 190 IBD patients diagnosed in the First Affiliated Hospital of Anhui Medical University from June 2017 to December 2019 were analyzed prospectively, including 103 patients with Crohn’s disease (CD) and 87 patients with ulcerative colitis (UC) . And 107 patients with gastrointestinal polyposis were set as control group. The serum level of anti-CABP, anti- Saccharomyces cerevisiae antibodies (ASCA) and perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) were detected in CD, UC and control groups by using ELISA. The differences in the serum level and positive rates of anti-CABP, ASCA and pANCA among the three groups were analyzed statistically. The diagnostic value of anti-CABP was evaluated by using receiver operating characteristic (ROC) analysis. The correlation between anti-CABP and clinical characteristics of IBD was analyzed. Results:The levels of anti-CABP IgA[14.46 (7.77, 34.71) U/ml vs. 10.22 (5.71, 14.98) U/ml and 6.60 (5.04, 8.38) U/ml, both P<0.01], anti-CABP IgG [11.12 (4.48, 42.31) U/ml vs. 5.26 (3.28, 10.02) U/ml and 2.85 (2.41, 3.52) U/ml, both P<0.01] and ASCA IgG[5.59 (2.68, 11.36) U/ml vs. 2.63 (1.42, 6.40) U/ml and 2.19 (1.20, 4.03) U/ml, both P<0.01] of CD patients were significantly higher than those of UC patients and control group. The pANCA level in UC patients was significantly higher than that of CD and control groups [8.55 (4.06, 19.98) U/ml vs. 2.91 (2.09, 3.99) U/ml and 1.65 (1.24, 2.23) U/ml, both P<0.01]. The positive rate of anti-CABP was 45.63% in CD patients, which was obviously higher than 4.60% in UC patients ( P<0.01) . Anti-CABP could effectively distinguish CD from non-CD patients (AUC 0.840) , and the diagnostic efficacy of anti-CABP was better than that of ASCA (AUC 0.708) . The combined use of three antibodies (anti-CABP, ASCA and pANCA) significantly improved the diagnostic value and the AUC was 0.892. The positive rate of anti-CABP IgA was not related with the clinical characteristics of IBD (all P>0.05) , while the positive rate of anti-CABP IgG was significantly different in the disease locations of CD patients ( P = 0.016) . Conclusion:The positive rate of anti-CABP in CD patients is significantly higher than that in UC patients, which suggests that the anti-CABP can be used as a serological marker to assist diagnosis and differential diagnosis of CD.

Objective:To explore the clinical significance of anti-Crohn′s disease antibody binding polypeptide (anti-CABP) in the diagnosis of inflammatory bowel disease (IBD) .Methods:Clinical data of 190 IBD patients diagnosed in the First Affiliated Hospital of Anhui Medical University from June 2017 to December 2019 were analyzed prospectively, including 103 patients with Crohn’s disease (CD) and 87 patients with ulcerative colitis (UC) . And 107 patients with gastrointestinal polyposis were set as control group. The serum level of anti-CABP, anti- Saccharomyces cerevisiae antibodies (ASCA) and perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) were detected in CD, UC and control groups by using ELISA. The differences in the serum level and positive rates of anti-CABP, ASCA and pANCA among the three groups were analyzed statistically. The diagnostic value of anti-CABP was evaluated by using receiver operating characteristic (ROC) analysis. The correlation between anti-CABP and clinical characteristics of IBD was analyzed. Results:The levels of anti-CABP IgA[14.46 (7.77, 34.71) U/ml vs. 10.22 (5.71, 14.98) U/ml and 6.60 (5.04, 8.38) U/ml, both P<0.01], anti-CABP IgG [11.12 (4.48, 42.31) U/ml vs. 5.26 (3.28, 10.02) U/ml and 2.85 (2.41, 3.52) U/ml, both P<0.01] and ASCA IgG[5.59 (2.68, 11.36) U/ml vs. 2.63 (1.42, 6.40) U/ml and 2.19 (1.20, 4.03) U/ml, both P<0.01] of CD patients were significantly higher than those of UC patients and control group. The pANCA level in UC patients was significantly higher than that of CD and control groups [8.55 (4.06, 19.98) U/ml vs. 2.91 (2.09, 3.99) U/ml and 1.65 (1.24, 2.23) U/ml, both P<0.01]. The positive rate of anti-CABP was 45.63% in CD patients, which was obviously higher than 4.60% in UC patients ( P<0.01) . Anti-CABP could effectively distinguish CD from non-CD patients (AUC 0.840) , and the diagnostic efficacy of anti-CABP was better than that of ASCA (AUC 0.708) . The combined use of three antibodies (anti-CABP, ASCA and pANCA) significantly improved the diagnostic value and the AUC was 0.892. The positive rate of anti-CABP IgA was not related with the clinical characteristics of IBD (all P>0.05) , while the positive rate of anti-CABP IgG was significantly different in the disease locations of CD patients ( P = 0.016) . Conclusion:The positive rate of anti-CABP in CD patients is significantly higher than that in UC patients, which suggests that the anti-CABP can be used as a serological marker to assist diagnosis and differential diagnosis of CD.

Objective:To explore the clinical significance of anti-Crohn′s disease antibody binding polypeptide (anti-CABP) in the diagnosis of inflammatory bowel disease (IBD) .Methods:Clinical data of 190 IBD patients diagnosed in the First Affiliated Hospital of Anhui Medical University from June 2017 to December 2019 were analyzed prospectively, including 103 patients with Crohn’s disease (CD) and 87 patients with ulcerative colitis (UC) . And 107 patients with gastrointestinal polyposis were set as control group. The serum level of anti-CABP, anti- Saccharomyces cerevisiae antibodies (ASCA) and perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) were detected in CD, UC and control groups by using ELISA. The differences in the serum level and positive rates of anti-CABP, ASCA and pANCA among the three groups were analyzed statistically. The diagnostic value of anti-CABP was evaluated by using receiver operating characteristic (ROC) analysis. The correlation between anti-CABP and clinical characteristics of IBD was analyzed. Results:The levels of anti-CABP IgA[14.46 (7.77, 34.71) U/ml vs. 10.22 (5.71, 14.98) U/ml and 6.60 (5.04, 8.38) U/ml, both P<0.01], anti-CABP IgG [11.12 (4.48, 42.31) U/ml vs. 5.26 (3.28, 10.02) U/ml and 2.85 (2.41, 3.52) U/ml, both P<0.01] and ASCA IgG[5.59 (2.68, 11.36) U/ml vs. 2.63 (1.42, 6.40) U/ml and 2.19 (1.20, 4.03) U/ml, both P<0.01] of CD patients were significantly higher than those of UC patients and control group. The pANCA level in UC patients was significantly higher than that of CD and control groups [8.55 (4.06, 19.98) U/ml vs. 2.91 (2.09, 3.99) U/ml and 1.65 (1.24, 2.23) U/ml, both P<0.01]. The positive rate of anti-CABP was 45.63% in CD patients, which was obviously higher than 4.60% in UC patients ( P<0.01) . Anti-CABP could effectively distinguish CD from non-CD patients (AUC 0.840) , and the diagnostic efficacy of anti-CABP was better than that of ASCA (AUC 0.708) . The combined use of three antibodies (anti-CABP, ASCA and pANCA) significantly improved the diagnostic value and the AUC was 0.892. The positive rate of anti-CABP IgA was not related with the clinical characteristics of IBD (all P>0.05) , while the positive rate of anti-CABP IgG was significantly different in the disease locations of CD patients ( P = 0.016) . Conclusion:The positive rate of anti-CABP in CD patients is significantly higher than that in UC patients, which suggests that the anti-CABP can be used as a serological marker to assist diagnosis and differential diagnosis of CD.

Objective:To explore the clinical significance of anti-Crohn′s disease antibody binding polypeptide (anti-CABP) in the diagnosis of inflammatory bowel disease (IBD) .Methods:Clinical data of 190 IBD patients diagnosed in the First Affiliated Hospital of Anhui Medical University from June 2017 to December 2019 were analyzed prospectively, including 103 patients with Crohn’s disease (CD) and 87 patients with ulcerative colitis (UC) . And 107 patients with gastrointestinal polyposis were set as control group. The serum level of anti-CABP, anti- Saccharomyces cerevisiae antibodies (ASCA) and perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) were detected in CD, UC and control groups by using ELISA. The differences in the serum level and positive rates of anti-CABP, ASCA and pANCA among the three groups were analyzed statistically. The diagnostic value of anti-CABP was evaluated by using receiver operating characteristic (ROC) analysis. The correlation between anti-CABP and clinical characteristics of IBD was analyzed. Results:The levels of anti-CABP IgA[14.46 (7.77, 34.71) U/ml vs. 10.22 (5.71, 14.98) U/ml and 6.60 (5.04, 8.38) U/ml, both P<0.01], anti-CABP IgG [11.12 (4.48, 42.31) U/ml vs. 5.26 (3.28, 10.02) U/ml and 2.85 (2.41, 3.52) U/ml, both P<0.01] and ASCA IgG[5.59 (2.68, 11.36) U/ml vs. 2.63 (1.42, 6.40) U/ml and 2.19 (1.20, 4.03) U/ml, both P<0.01] of CD patients were significantly higher than those of UC patients and control group. The pANCA level in UC patients was significantly higher than that of CD and control groups [8.55 (4.06, 19.98) U/ml vs. 2.91 (2.09, 3.99) U/ml and 1.65 (1.24, 2.23) U/ml, both P<0.01]. The positive rate of anti-CABP was 45.63% in CD patients, which was obviously higher than 4.60% in UC patients ( P<0.01) . Anti-CABP could effectively distinguish CD from non-CD patients (AUC 0.840) , and the diagnostic efficacy of anti-CABP was better than that of ASCA (AUC 0.708) . The combined use of three antibodies (anti-CABP, ASCA and pANCA) significantly improved the diagnostic value and the AUC was 0.892. The positive rate of anti-CABP IgA was not related with the clinical characteristics of IBD (all P>0.05) , while the positive rate of anti-CABP IgG was significantly different in the disease locations of CD patients ( P = 0.016) . Conclusion:The positive rate of anti-CABP in CD patients is significantly higher than that in UC patients, which suggests that the anti-CABP can be used as a serological marker to assist diagnosis and differential diagnosis of CD.

Objective: To investigate the effects of milrinone on levels of inflammatory factors and liver and renal function after CPB in rheumatic heart disease patients for valve replacement. Methods: From January 2014 to January 2016, 80 patients received valve replacement in the Central Hospital of Chongqing Three Gorges were randomly divided into observation group and control group by block randomization grouping method, with 40 patients in each group.The patients in the observation group were pumped intravenously with milrinone 0.5μg·kg^-1·min^-1 for 72h after surgery, while the patients in the control group were not pumped.The serum levels of IL-6, IL-8, IL-10, TNF-α were detected by ELISA before operation and on 0d, 1d, 3d, 5d after operation, respectively.The levels of ALT, AST, Scr were also detected at the same time.Moreover, the time for operation, extracorporeal circulation, interruption, mechanical ventilation, ICU and hospital were also compared between the two groups. Results: The levels of TNF-α, IL-6, IL-8 and IL-10 increased immediately after operation in both groups[control group: (14.97±5.14)pg/mL, (52.45±10.37)pg/mL, (34.10±8.38)pg/mL, (32.27±8.45)pg/mL; observation group: (16.05±5.71)pg/mL, (54.39±8.56)pg/mL, (33.80±7.69)pg/mL, (31.48±5.94)pg/mL, t=-0.628, -0.644, 0.116, 0.342], and the peak values of TNF-α, IL-6 and IL-8 reached on the first day after operation in both two groups[control group: (52.07±10.18)pg/mL, (96.04±26.45)pg/mL, (91.14±18.28)pg/mL, (48.10±9.78)pg/mL; observation group: (50.37±12.98)pg/mL, (93.66±24.10)pg/mL, (83.16±16.28)pg/mL, (46.68±9.25)pg/mL, t=0.559, 0.295, 1.458, 0.473], and the peak value of IL-10 reached on the 3rd day after operation(t=-3.577), the differences were statistically significant on the 3rd day after operation[control group: (36.03±9.39)pg/mL, (59.56±14.38)pg/mL, (53.91±13.16)pg/mL, (85.55±16.49)pg/mL; observation group: (36.70±4.33)pg/mL, (36.20±3.85)pg/mL, (42.91±7.30)pg/mL, (101.33±10.81)pg/mL, t=-0.289, 7.017, 3.267, -3.577]. The levels of ALT, AST and Scr increased immediately after operation in both groups[control group: (38.51±5.12)U/L, (40.23±5.03)U/L, (62.27±5.02)μmol/L; observation group: (39.20±4.67)U/L, (39.6±4.94)U/L, (73.61±4.04)μmol/L, t=0.114, 0.243, 0.630], there were tatistically significant difference between the two groups on the 5th day after operation[control group: (61.45±5.27)U/L, (54.20±7.0)U/L, (86.45±9.01)μmol/L; observation group: (36.20±3.85)U/L, (34.85±7.12)U/L, (83.7±11.07)μmol/L, t=11.231, 9.224, 5.647], and on the fifth day, the levels of ALT, AST and Scr in the observation group dropped to normal, while only the level of Scr in the control group dropped to normal.There were no statistically significant differences in the time of operation, extracorporeal circulation, interruption, mechanical ventilation between two groups (t=0.267, 0.151, 0.187, 0.773, all P>0.05). However, there were statistically significant differences in the time of ICU and hospital [control group: (54.90±16.84)h, (14.35±3.01)d, observation group: (44.05±7.06)h, (10±1.86)d, t=8.149, 13.042, all P<0.05]. Conclusion Milrinone can obviously improve the inflammatory reaction in surgical trauma tissues caused by IL-6, IL-8, IL-10, TNF-α, and can protect liver, renal tissue from injury, moreover, it can decrease the incidence of postoperative complications and the length of hospital stay.

Objective To observe the intervention effects of fluid wax on the therapeutic course of patients with adhesive small bowel obstruction.Methods Two hundreds and eighty-eight patients with adhesive small bowel obstruction admitted into the Department of Gastrointestinal Surgery of Huzhou Central Hospital from December 2014 to June 2016 were enrolled, and they were divided into a fluid wax group and acontrol group by mechanical sampling method, each group 144 cases. The control group was treated with conventional comprehensive non-surgical treatment, in the fluid wax group, on the basis of the above conventional treatment, additionally after 2 hours of gastrointestinal decompression, the fluid wax 3 mL/kg was injected through a gastric tube that then was closed by a clip for 2 hours. The first exhaust and defecation times, the time for amelioration of abdominal pain, the time of gas-liquid flat disappearance, the length of stay in hospital, the rate of operation and the occurrence of adverse reactions were observed in the two groups.Results After treatment, the first exhaust time, the first defecation time, the time of relieving abdominal pain, the time of gas-liquid flat disappearance and the length of stay in hospital were significantly shorter in fluid wax group than those in control group [the first exhaust time (hours): 29.97±19.71 vs. 49.28±33.61, the first defecation time (hours): 60.25±28.37 vs.74.23±50.12, the time of relieving abdominal pain (hours): 35.78±20.98 vs. 51.83±25.02, the time of gas-liquid flat disappearance (hours): 71.60±39.50 vs. 90.98±57.91, the length of stay in hospital (days): 7.00±3.77 vs. 9.00±5.81, allP < 0.05], and the rate of operation in the fluid wax group was lower than that in the control group [18.75% (27/144) vs. 27.08% (39/144),P < 0.05]. No patients died in the two groups. In nearly 1 year follow-up, there were no adverse reactions associated with the study in the fluid wax group.Conclusion The intervention of fluid wax combined with conventional non-surgical methods can significantly shorten the disease course, reduce the rate of operation and the hospitalization time in patients with adhesive small bowel obstruction.